Repligen Corporation — FY2015 Form 10-K
Business context and reporting period: Annual report for the fiscal year ended December 31, 2015, filed February 25, 2016. Repligen develops and sells bioprocessing products used to manufacture biologic drugs, including Protein A ligands, OPUS chromatography columns, growth factors and ATF systems. The company reports as one operating segment.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Total revenue | $83.5 million | $63.5 million |
| Product revenue | $83.5 million | $60.4 million |
| Gross margin | 58% | 54% |
| Operating income | $13.8 million | $10.7 million |
| Net income | $9.3 million | $8.2 million |
| Diluted earnings per share | $0.28 | $0.25 |
| Cash and marketable securities | $73.4 million | $62.0 million |
| Working capital | $84.5 million | $70.3 million |
| Operating cash flow | $15.1 million | $18.4 million |
- Product revenue grew 38%, mainly from increased affinity-ligand and ATF sales. Total revenue rose 31%; FY2015 included no royalty and other revenue, compared with $3.1 million in FY2014.
- Gross margin improved with favorable ATF margins, higher capacity utilization and product mix. SG&A increased 44% to $24.7 million, reflecting commercial expansion, administrative infrastructure and inventory-accounting software costs.
- Operating cash flow declined despite higher net income, with increased accounts receivable and inventory among the cash uses. Investing activities provided $4.8 million, mainly from net redemptions of marketable securities; capital expenditures were $2.6 million.
- At year-end, total liabilities were $23.5 million, including $18.8 million current liabilities and $4.7 million other long-term liabilities. The filing does not identify conventional borrowings as a material funding source; reported long-term obligations should not be read as debt without checking the notes.
- Fourth-quarter 2015 revenue was $21.4 million and net income was $0.3 million, compared with $16.4 million revenue and a $0.4 million net loss in Q4 2014.
Material changes, outlook and risks
- Repligen continued its shift toward bioprocessing and direct sales. Product revenue increased from $60.4 million in 2014 to $83.5 million in 2015; the filing attributes growth principally to higher affinity-ligand and ATF volumes.
- Management expected 2016 operating expenses, including bioprocessing R&D and SG&A, to increase as the company expanded product development and commercial capabilities. No quantified revenue or earnings guidance is provided.
- Management said existing cash was sufficient for at least 24 months, absent acquisitions. Acquisitions or weaker product demand could create additional financing needs.
- GE Healthcare and MilliporeSigma represented 37% and 29% of FY2015 revenue, respectively. The filing identifies customer concentration, order timing and customer purchasing changes as significant risks.
- Other key risks include competition, adoption of newer products, dependence on a limited supplier base for ATF materials, manufacturing and quality disruptions, foreign-exchange exposure, and managing international operations. 33% of FY2015 revenue and 23% of costs and expenses were denominated in foreign currencies; the company did not hedge this exposure.
- Refine-related contingent consideration was $6.8 million at year-end, and the company recorded $4.1 million of fair-value adjustment expense in 2015. Additional Refine payments of up to $9.9 million could be due if milestones are achieved; amounts and timing are uncertain.
- The Bristol-Myers Squibb Orencia royalty stream had ended after 2013. Pfizer terminated its spinal muscular atrophy license effective April 2015. BioMarin may owe Repligen up to $160 million in future milestones plus royalties under the HDACi agreement, contingent on development and commercialization.
- The company reported no material legal proceedings. Management and Ernst & Young concluded internal control over financial reporting was effective; the auditor issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- Whether product growth and margin improvement continue as ATF and OPUS adoption develops, and how much growth depends on the two largest customers.
- Cash conversion and working-capital needs, particularly receivables and inventory, alongside expected 2016 spending growth.
- The assumptions and potential payment timing behind the $6.8 million contingent-consideration liability and Refine earnout.
- Whether the company’s supplier contingency plans adequately address ATF’s limited qualified supply sources.
- Any progress, milestones or royalties under the BioMarin agreement; the potential payments are conditional, not assured.